Dr Reddy's Laboratories (FRA:RDDA) Additional Paid-In Capital : €0 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Dr Reddy's Laboratories Additional Paid-In Capital?

Dr Reddy's Laboratories's quarterly additional paid-in capital declined from Sep. 2023 (€122 Mil) to Dec. 2023 (€120 Mil) but then stayed the same from Dec. 2023 (€120 Mil) to Mar. 2024 (€0 Mil).

Dr Reddy's Laboratories's annual additional paid-in capital declined from Mar. 2022 (€116 Mil) to Mar. 2023 (€116 Mil) and declined from Mar. 2023 (€116 Mil) to Mar. 2024 (€0 Mil).

Dr Reddy's Laboratories Additional Paid-In Capital Historical Data

The historical data trend for Dr Reddy's Laboratories's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Additional Paid-In Capital Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Additional Paid-In Capital

Get a 7-Day Free Trial

105.23

104.51

116.28

116.27

Dr Reddy's Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															116.27	112.10	121.80	120.00	-

Dr Reddy's Laboratories Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Dr Reddy's Laboratories Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (FRA:RDDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (FRA:RDDA) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

RDY:USA DRREDDY:India 500124:India RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (FRA:RDDA) Headlines

No Headlines